1Anno·

Healthcare sector thus also covered and most convinced by J&J🙈🐵

10.09

Johnson&Johnson

Acquistato x7 a 152,56 €

1067,94 €

6 Commenti

Tojasoku@Tojasoku

1Anno

For what reason J&J?

•

UnknownMakaroV601@UnknownU

1Anno

@Tojasoku I would be interested in that too. I would also be interested to know who was in the comparison group and why they decided against others🤔

•

DividendenAffe@Jico

1Anno

J&J had a strong correction has now recovered already 2% divi + strong growth in my eyes and in my opinion they have no more hurdles ahead of them in the near future and will grow solidly. Novo nordisk & CVS health were still in the selection...

••

Tojasoku@Tojasoku

1Anno

@Jico Have you looked further into the products? It's always interesting to see what's in the pipeline, especially with pharmaceuticals.

••

CrashBurner@Psychedelic_Sunflower

1Anno

Not every sector has to be covered. Pharma is difficult. You either have to be able to assess the pipeline quite well and still move in highly speculative spheres or you have enormously sporty valued companies in front of your nose or, as in the case of Johnson & Johnson, a blue chip portfolio brake with only moderate growth and the constant danger of slipping into some pharmaceutical scandal.

•

Peace@Pinkafeld

1Anno

J&j falls. Abott and Amgen are more stable

••